Please login to the form below

Not currently logged in
Email:
Password:

TCR-T

This page shows the latest TCR-T news and features for those working in and with pharma, biotech and healthcare.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Under the terms of the latest deal, Immatics will be in charge of taking the TCR projects through to the stage where a clinical candidate has been identified, with GSK taking ... TCR therapies are emerging as a new type of cell therapy that involves

Latest news

  • Newly-listed BioNTech buys Neon to boost cell therapy assets Newly-listed BioNTech buys Neon to boost cell therapy assets

    BioNTech said the deal would expand its CAR-T and T cell receptor (TCR) pipeline, allowing it to tap into Neon’s portfolio of cancer neoantigens – newly formed antigens that have ... executive. “I am particularly excited about the adoptive T cell

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    Immatics’ XPRESIDENT technology and XCEPTOR TCR discovery and engineering platform are tailored to developing effective TCR-T cell therapies. ... Celgene will also be able to manufacture and gain worldwide commercialisation rights to the TCR-T cell

  • CAR-T player Autolus seeks $100m from follow-on financing CAR-T player Autolus seeks $100m from follow-on financing

    The Nasdaq-listed biotech company - considered one of the brightest prospects of the UK biotech sector thanks to its promising CAR-T and TCR technologies – says it will use the net ... approved CAR-T Kymriah (tisagenlecleucel) – which recently

  • Roivant forms Asian cell therapy ‘vant’, with Medigene’s help Roivant forms Asian cell therapy ‘vant’, with Medigene’s help

    The deal with Medigene covers rights to a research-stage T cell receptor (TCR) against tumour antigen NY-ESO-1 and Medigene’s dendritic cell vaccine targeting WT-1 and PRAME ... The two companies work also together on two additional TCR projects that

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    Extends partnership to target MAGE-A4 protein tumours. Roche’s Genentech is to build on its existing partnership with T cell receptor (TCR) specialists Immunocore, and this time around the companies ... Those molecules are based on soluble, engineered

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch September 2016 Deal Watch September 2016

    1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready, includes upfront of $15m. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies

  • Deal Watch February 2016 Deal Watch February 2016

    The ARCUS technology enables the production of CAR T-cells derived from healthy donors (i.e. ... licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting

  • Pharma deals in June 2015 Pharma deals in June 2015

    therapeutic strategies, and initially on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2). ... Collaboration. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics